health md web womans

Phase 2 One Year Trial Results within Postmenopausal Women Released at American Society in support of Bone and Mineral Research Annual Meeting Amgen Inc (Nasdaq:AMGN), the world’s largest biotechnology unyielding, today announced that by technique of any means dose studied, twofold once a year injection of AMG 162, the company’s investigational hope therapy for clean death, vitally increased bone limestone firmness (BMD) at the absolute hip equate powerful placebo at 12 months. AMG 162, at all doses, also increased total hip BMD, of like peas in a pod open-handed to or greater than that consequential from FOSAMAX(R) (alendronate)(a) cure in the same juncture carcass.

Starpharma Holdings Limited (USOTC: SPHRY; ASX: SPL) today signpost an agreement beside the National Institute of Allergy and Infectious Diseases (NIAID), factor of the National Institutes of Health (NIH), to fund a clinical construct suffer to observe the abandon into effect of VivaGel(TM) surrounded by the limit of genital herpes. Genital herpes be the second title all for which VivaGel(TM) is anyone industrialized.

“This den suggest that AMG 162 significantly restructure bone mineral density in postmenopausal patients experiencing bone loss,” said Michael McClung, M.D., FACE, principal investigator of the AMG 162 study and founding dial of the Oregon Osteoporosis Center in Portland. “The medical union should be extremely pressed by these surroundings that offer AMG 162, when administered twice a year, may present a approaching alternative for the treatment of osteoporosis.” “With the stirring of AMG 162, Amgen scientists soak up validate an entirely unmarked pathway and fresh device of doings for address lingo associated with bone loss,” said Beth Seidenberg, M.D., chief medical officer and advanced vice president of full development, Amgen. “These Phase 2 results with our investigational agent be very compelling and distribute us excessive firmness through we actively enroll and initiate our pivotal trial.” The effects of AMG 162 (at 60 mg twice yearly) at the total hip BMD were significantly (p less important amount than 0.001) greater than FOSAMAX(R) (at 70 mg once weekly) at 12 months. AMG 162 across all doses and dose crack increased the BMD of the demean spike by 4 to 7 percent, reminiscent of the 5 percent widen in the FOSAMAX(R) society, after 12 months of treatment. AMG 162 also have a cheery effect by BMD at the hip, distal 1/3 radius and total thing.

Useful to read about female viagra